Find recruiting clinical trials for ovarian cancer in the UK — from first-line chemotherapy to PARP inhibitors and immunotherapy. See where trials fit into your treatment pathway.
Free to use · Live data from ClinicalTrials.gov · Updated daily
See where clinical trials fit into your treatment journey
Primary treatment involves debulking surgery followed by platinum-based chemotherapy
Standard: Carboplatin + paclitaxel (6 cycles) after optimal cytoreductive surgery
After chemotherapy response, PARP inhibitors maintain remission — especially for BRCA-mutated tumours
Standard: Olaparib, niraparib, or rucaparib as maintenance therapy (2–3 years)
Added to chemotherapy and continued as maintenance for high-risk disease
Standard: Bevacizumab alongside carboplatin/paclitaxel, then continued as single agent
For platinum-resistant relapse, trials explore immune checkpoint inhibitors and antibody-drug conjugates
Emerging: Pembrolizumab, dostarlimab, mirvetuximab soravtansine (FRα-targeted ADC)
Ovarian cancer is the 6th most common cancer in UK women, with about 7,500 new cases per year. It often presents at a late stage because early symptoms (bloating, abdominal pain, feeling full quickly) are vague. High-grade serous carcinoma is the most common subtype.
Despite advances in PARP inhibitors, most ovarian cancer patients still relapse. Only about 35% survive 10+ years. Trials are testing new combinations, ADCs, bispecific antibodies, and personalised vaccine approaches that could significantly improve outcomes.
About 15-20% of ovarian cancers are linked to BRCA1/2 gene mutations. All ovarian cancer patients in the NHS should be offered genetic testing. BRCA-mutated tumours respond especially well to PARP inhibitors, making them prime candidates for targeted therapy trials.
Loading trials from ClinicalTrials.gov...